Inhibrx Biosciences Inc.

NASDAQ: INBX · Healthcare · Biotechnology

PublicHQ La Jolla, CACIK 0002007919Reports USD

#840 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

28D

FH 28DQ 22GM —SS 51

v0.1 · 55/100 weight · provisional

↑ revenue growth (YoY), market scale · ↓ return on equity, listing tenure

Methodology →

Revenue TTM

$1.3M

Rev growth YoY (TTM)

+550.0%

Net income (FY)

-$140.1M

Employees

109

Market cap

$1.4B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.3M$1.3M2025

Net income-$140.1M-$140.1M2025

Operating income-$135.0M-$135.0M2025

Total assets$146.5M$146.5M2025

Liabilities$138.5M$138.5M2025

Equity$8.0M$8.0M2025

Revenue trend

FY2024 – FY2025 · USD

$1.8M

FY24

$200.0k

FY24

$1.3M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

License, Non-Affiliate100%

By geography

Not disclosed.

The read

Inhibrx Biosciences Inc. booked $1.3M in FY2025 revenue, growing 550% year over year — faster than 95% of Healthcare companies we track, at a -10773.5% net margin.

Peers · Healthcare

Xeris Biopharma Holdings, Inc.65B Rapport Therapeutics, Inc. Common Stock——Integra LifeSciences Holdings Corporation67B AdaptHealth Corp.67B

Key facts

CEOMark Lappe

SectorHealthcare

IndustryBiotechnology

HeadquartersLa Jolla, CA

ExchangeNASDAQ: INBX

Employees109

IPO date2024-05-29

Latest filings

8-K2026-06-15 8-K2026-06-03 8-K2026-05-14 10-Q2026-05-14 8-K2026-05-11 DEF 14A2026-04-23 8-K2026-04-21 8-K2026-03-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.